Moderna and Merck report that their personalised mRNA vaccine, added to standard treatment, cut the risk of death or recurrence by 42% in a Phase 3 trial of 1,137 patients with surgically removed stage IIB-IV melanoma, with details presented at the ESMO congress in Madrid. Ars Technica
Ars TechnicaModerna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%Markers released top-line results today after previously reporting the trial succeeded.
If this holds up through regulatory review, which other cancers do you think personalised vaccines could reach first?
